Investing.com - Ascendis Pharma AS (NASDAQ: ASND) reported third quarter EPS of €-2.16, €0.37 better than the analyst estimate of €-2.53. Revenue for the quarter came in at €47.4M versus the consensus estimate of €37.37M.
Guidance
Ascendis Pharma AS sees FY 2023 revenue of €150.00M-€160.00M
Ascendis Pharma AS's stock price closed at €99.74. It is up 7.64% in the last 3 months and up 12.96% in the last 12 months.
Ascendis Pharma AS saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Ascendis Pharma AS's stock price’s past reactions to earnings here.
According to InvestingPro, Ascendis Pharma AS's Financial Health score is "fair performance".
Check out Ascendis Pharma AS's recent earnings performance, and Ascendis Pharma AS's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar